Drugs & Targets MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D September 16, 2022Vol.48 No.33
Drugs & Targets OU Health Stephenson Cancer Center joins Caris’ Precision Oncology Alliance September 16, 2022Vol.48 No.33
Drugs & Targets Strata Oncology, Carbone Cancer Center integrate StrataNGS test results with Epic Genomics Module September 16, 2022Vol.48 No.33
Drugs & Targets Indivumed and CELLphenomics form partnership for improved patient care in EU-funded project September 16, 2022Vol.48 No.33
Drugs & Targets FDA approves first targeted therapy for HER2-low breast cancer September 09, 2022Vol.48 No.32
Drugs & Targets FDA grants accelerated approval to Enhertu for HER2-mutant NSCLC and companion diagnostic September 09, 2022Vol.48 No.32
Drugs & Targets FDA approves Incyte’s Pemazyre as first and only targeted treatment for myeloid/lymphoid neoplasms with FGFR1 rearrangement September 09, 2022Vol.48 No.32
Drugs & Targets FDA approves darolutamide for metastatic hormone-sensitive prostate cancer September 09, 2022Vol.48 No.32
Drugs & Targets FDA approves Tabrecta for metastatic NSCLC with mesenchymal-epithelial transition exon 14 skipping September 09, 2022Vol.48 No.32
